Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Press Release - October 1, 2012
Select one of the options below to save this article to your library.
READING, U.K. - Oct 1, 2012 - Quintiles today announced a strategic partnership with the four teaching health boards - Aberdeen, Dundee, Edinburgh and Glasgow - in Scotland as part of its Prime Site program to accelerate the development of new and more effective medicines.
According to National Health Service Research Scotland (NRS) and other health organizations, while the overall health of Scotland's citizens is improving, it remains below that of other Western European countries. This strategic partnership is designed to increase access to clinical trials for both patients and investigators, accelerating the collection of data about the safety and efficacy of investigational therapies. Scotland is attractive for this because:
The partnership builds on Quintiles' long experience and success in working with NHS Scotland's four university-based academic research centers in Aberdeen, Dundee, Edinburgh and Glasgow. These sites have broad therapeutic expertise and a reputation for high-quality research. With about 30 Quintiles studies open at any one time and the Scottish government's Chief Scientist Office strongly focused on metrics, Scotland has the foundation to be a leader in clinical trial recruitment and study start-up.
As part of the partnership, Quintiles will introduce new technology that uses electronic health records to improve the identification of patients for potential inclusion in clinical research.
"Scotland has a significant burden of disease and a huge need to speed the development of new therapies that will help people live healthier lives," said Lindy Jones, global head of Integrated Site Services, Quintiles. "We have a successful track record of collaboration with Scottish government and health care organizations. This partnership will further enhance our ability to recruit patients and investigators - two groups critical to an efficient and effective drug development process."
Scotland Cabinet Secretary for Health and Well-Being Alex Neil, said "These developments demonstrate the importance that we place on research within NHS Scotland, and will help to further enhance Scotland's growing reputation as a global centre of excellence for clinical research. Bringing more research trials to Scotland will reap benefits for patients, by speeding up the development of new medical therapies and enhancing the health care treatment options that are on offer for patients. Continued investment in clinical research will undoubtedly bring great health and wealth benefits to Scotland."
Quintiles is the world's leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
Charlotte Taylor, Media RelationsOffice: +44 1344 708386
Greg Connors, Investor RelationsOffice: +1 919 998 2000
Mari Mansfield, Media RelationsOffice: +1 919 998 2639